Bonum Therapeutics
Wendy Curtis is a seasoned scientist with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as a Scientist at Bonum Therapeutics since September 2022, Wendy previously held the same title at Good Therapeutics, Inc. from April 2019 to September 2022. Prior roles include Associate Scientist in In Vivo Pharmacology at Juno Therapeutics, Inc. from 2016 to April 2019, Associate Scientist and Research Associate III in Immuno-Oncology at Bristol-Myers Squibb from 2008 to 2016, and various research positions at ZymoGenetics and the University of Washington. Wendy earned a BS in Cell and Molecular Biology and a BA in Norwegian from the University of Washington in 2001.
Bonum Therapeutics
Bonum Therapeutics is creating a technology platform that can be used to treat a wide range of diseases, including cancer which is the company’s primary therapeutic area of focus—as well as metabolic diseases, immunology, and pain management.